FindTrial
Sign In

Randomized phase III study of S-1 plus oxaliplatin compared with S-1 plus cisplatin as first-line therapy for advanced or recurrent gastric cancer

Randomized phase III study of S-1 plus oxaliplatin compared with S-1 plus cisplatin as first-line therapy for advanced or recurrent gastric cancer

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220988
Enrollment
Unknown
Registered
2010-01-13
Start date
2010-01-13
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced or recurrent gastric cancer

Interventions

investigational material(s) Generic name etc : Oxaliplatin INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational mater

Sponsors

Yakult Honsha Co.,Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: -Gastric cancer confirmed by histological diagnosis or cytologic diagnosis -Advanced/Recurrent gastric cancer -Not pretreated with chemotherapy drugs, immunotherapeutic drugs, or radiation therapy -ECOG Performance Status 0 to 2

Exclusion criteria

Exclusion criteria:

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026